The Patent Finder
CH

Chiron Corporation

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
45 more records may belong here and await a decision; they are not counted.

This portfolio holds none of the 3 US patents in force on its record. from the record

Of the 3 now held by other companies, 1 name Novartis Vaccines and Diagnostics Inc. as their current owner, and 2 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2010 to 2031.
US 8,217,035 Pyrimidine Derivatives Used as PI-3-Kinase Inhibitors Dec 5, 2027
US 7,754,686 Stabilized FGF Formulations Containing Reducing Agents Nov 11, 2028
US 9,393,215 Nanoparticles For Use In Immunogenic Compositions Mar 24, 2031
201420182022202620302031
Every computed term in this portfolio is shown above.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 108 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2027.
now held by Novartis AG
Ends Dec 2027 · High confidence
Also notable
Cited by 77 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Mar 2031 · High confidence
Also notable
Renewed at every maintenance window since the 2010 grant; no more fees are due before its term ends in 2028.
Ends Nov 2028 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 16, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Also on record: 3 patents in force now held by others · 113 patents ended · 100 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term
12 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
33 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited